Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study

Table 2 Bivariate, and age/sex adjusted regression results (hazard ratios and 95% confidence intervals) for each exposure definition with time to lung cancer diagnosis as the outcome

Exposure Metrics	Bivariate			Age and Sex Adjusted
Exposure Metrics	HR	95% CI LL	95% CI UL	HR	95% CI LL	95% CI UL
Time-dependent statin exposure	0.88	0.76	1.02	0.87	0.74	1.01
Cumulative Years of Use	0.97	0.91	1.02	0.96	0.91	1.02
Cumulative Dose^a	0.99	0.98	1.00	0.99	0.98	1.00
Recency-Weighted Cumulative Duration of Use	0.87	0.79	0.95	0.86	0.79	0.94
Recency-Weighted Cumulative Dose	0.98	0.96	0.99	0.98	0.96	0.99

HR hazard ratio, Ref reference category, CI confidence interval, LL lower limit, UL upper limit
^aMeasured as a continuous variable (grams)

ISSN: 1465-993X